Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2007

View Archived Issues

AV-411 shows promise as neuropathic pain treatment

Jerini establishes ophthalmic subsidiary

Indian researchers present findings on gefitinib and imatinib

Cleveland BioLabs to submit Protectan CBLB-502 in response to RFP

Sodium phenylbutyrate to enter clinical evaluation for spinal muscular atrophy

Recent patent literature covers new drugs for the treatment of immunological disorders.

New analgesic compounds have been reported in the patent literature

Evotec collaborates with Boehringer Ingelheim in Alzheimer's disease

Akesis in-licenses BEOV from U. of British Columbia

Both PHA-665752 and NK4 inhibit proliferation and migration of CRC cells

IL-10: A prognostic factor and a target for high-risk melanoma patients

HEP27: a novel target for selective VTAs

ChimeriVax-West Nile studied in older adults

Medtronic and OsteoGenix establish development agreement

Medistem introduces Tolerostem as second pipeline candidate

BioLineRx in-licenses BL-4020 for inflammatory disease

Avera licenses products from Cornell University

GlycoPEG-GCSF begins second phase I trial

Amarillo Biosciences updates interferon lozenge trial status

GW and Otsuka receive Hart-Scott-Rodino clearance for Sativex agreement

NINDS begins phase III study of PD-02 for Parkinson's disease

Viral Genetics updates progress in VGV-1 program

Eisai to acquire Morphotek

Long-term improvement in BPH patients given NX-1207

ACP-103 cotherapy provides highly significant antipsychotic efficacy

Removab may play role in treatment of ascites for non-ovarian cancers

Coreg CR now available in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.